RSS-Feed abonnieren
DOI: 10.1055/s-0030-1260546
Highly Diastereoselective Construction of Substituted Pyrrolidines: Formal Synthesis of (-)-Bulgecinine [¹]
Publikationsverlauf
Publikationsdatum:
05. Mai 2011 (online)

Abstract
A highly diastereoselective synthesis of substituted pyrrolidines has been achieved starting from nonchiral molecule, allyl bromide, or cis-but-2-ene-1,4-diol. The method involves the asymmetric epoxidation and endo-mode epoxide opening with azide nucleophile as the key steps. The method has been applied for the formal synthesis of (-)-bulgecinine.
Key words
substituted pyrrolidine - (-)-bulgecinine - diastereoselective synthesis - asymmetric epoxidation - endo-mode epoxide opening
Part 45 in the series ‘Synthetic Studies on Natural Products and Bioactive Compounds’.
-
2a
Cheng Y.Huang ZT.Wang MX. Curr. Org. Chem. 2004, 8: 325 -
2b
Michael JP. Nat. Prod. Rep. 2005, 22: 603 -
3a
Imada A.Kintaka K.Nakao M.Shinagawa S. J. Antibiot. 1982, 35: 1400 -
3b
Shinagawa S.Kashara F.Wada Y.Harada S.Asai M. Tetrahedron 1984, 40: 3465 -
3c
Shinagawa S.Maki M.Kintaka K.Imada A.Asai M. J. Antibiot. 1985, 38: 17 -
4a
Das B.Suneel K.Satyalakshmi G. Tetrahedron: Asymmetry 2009, 20: 1536 -
4b
Das B.Krishnaiah M.Sudhakar Ch. Bioorg. Med. Chem. Lett. 2010, 20: 2303 -
4c
Das B.Kumar DN. Tetrahedron Lett. 2010, 51: 6011 - Some earlier syntheses:
-
5a
Wakamiya T.Yamauoi K.Nishikawa M.Shiba T. Tetrahedron Lett. 1985, 26: 4739 -
5b
Bashyal BP.Chow HF.Fleet GWJ. Tetrahedron Lett. 1986, 27: 3205 -
5c
Fehn S.Burger K. Tetrahedron: Asymmetry 1997, 8: 2001 -
5d
Maeda M.Okazaki F.Murayama M.Tachibana Y.Aoyagi Y.Ohta A. Chem. Pharm. Bull. 1997, 45: 962 -
5e
Khalaf JK.Datta A. J. Org. Chem. 2004, 69: 387 -
5f
Chavan SP.Praveen Ch.Sharma P.Kalkote UR. Tetrahedron Lett. 2005, 46: 439 -
5g
Toumi M.Couty F.Evano G. Tetrahedron Lett. 2008, 49: 1175 -
6a
Izzo I.Scioscia M.Del Gaudio P.De Riccardis F. Tetrahedron Lett. 2001, 42: 5421 -
6b
Poulard C.Carnet J.Legoupy S.Dujardiu G.Dhal R.Huct F. Lett. Org. Chem. 2009, 6: 359 -
7a
Katsuki T.Sharpless KB. J. Am. Chem. Soc. 1980, 102: 5974 -
7b
Gao Y.Hanson RM.Klunder JM.Ko SY.Masamune H.Sharpless KB. J. Am. Chem. Soc. 1987, 109: 5765 -
7c
Goument B.Duchamel L.Mauge R. Tetrahedron 1994, 50: 171 -
8a
Ma P.Martin VS.Masumune S.Sharpless KB.Viti SM. J. Org. Chem. 1982, 47: 1378 -
8b
Finan JM.Kishi Y. Tetrahedron Lett. 1982, 23: 2719 - 9
Sasaki M.Tanino K.Hirai A.Miyashita MT. Org. Lett. 2003, 5: 1789
References and Notes
Part 45 in the series ‘Synthetic Studies on Natural Products and Bioactive Compounds’.
10
Spectral and Analytical
Data of Selected Compounds(3-{3-(Benzyloxy)-2-[(4-methoxybenzyl)oxy]propyl}-oxiran-2-yl)methanol
(4)
[α]D
²5 -16.8
(c 0.9, CHCl3). IR (KBr): νmax = 3449,
1455, 1375, 1248 cm-¹. ¹H
NMR (300 MHz, CDCl3): δ = 7.43-7.16
(7 H, m), 6.81 (2 H, d, J = 8.0
Hz), 4.65-4.43 (4 H, m), 3.79 (3 H, s), 3.74-3.63
(2 H, m), 3.62-3.42 (3 H, m), 2.99 (1 H, m), 2.82 (1 H,
m), 1.92-1.73 (2 H, m). ¹³C
NMR (75 MHz, CDCl3): δ = 158.3, 139.2,
13 2.3, 129.3, 128.8, 128.0, 121.9, 116.0, 73.2, 71.4, 70.7, 70.5,
70.3, 61.2, 56.3, 49.3, 30.7. ESI-MS: m/z = 358 [M]+.
Anal. Calcd (%) for C21H26O5:
C, 70.39; H, 7.26. Found: C, 70.41; H, 7.21.
2-Azido-6-(benzyloxy)-5-(4-methoxybenzyloxy)hexane-1,3-diol
(3)
IR (KBr): νmax = 3390,
2103 cm-¹. ¹H NMR
(200 MHz, CDCl3): δ = 7.38-7.16
(7 H, m), 6.81 (2 H, d, J = 8.0
Hz), 4.65-4.44 (4 H, m), 4.07 (1 H, m), 3.85 (1 H, m),
3.78 (3 H, s), 3.56-3.47 (4 H, m), 2.09 (1 H, m), 1.99-1.78
(1 H, m). ¹³C NMR (100 MHz, CDCl3): δ = 158.0,
137.8, 129.5, 128.5, 127.7, 126.7, 116.0, 73.2, 72.8, 70.1, 66.1,
65.5, 62.6, 55.9, 29.8. ESI-MS: m/z = 401 [M]+.
Anal. Calcd (%) for C21H27N3O5:
C, 62.84; H, 6.73. Found: C, 62.80; H, 6.75.
(4a
R
,6
S
,7a
S
)-6-(Benzyloxymethyl)-2,2-dimethyl-hexahydro[1,3]dioxino[5,4-
b
]pyrrole
(16)
[α]D
²5 +31.3
(c 1.7, CHCl3). IR (KBr): νmax = 3385,
1600, 1490, 1279 cm-¹. ¹H
NMR (300 MHz, CDCl3): δ = 7.37-7.20
(5 H, m), 4.53 (2 H, s), 4.22 (1 H, m), 4.08 (1 H, m), 3.47 (1 H,
m), 3.33 (1 H, m), 2.93-2.74 (3 H, m), 2.30 (1 H, m), 1.97-1.71
(2 H, m), 1.48 (6 H, s). ¹³C NMR (75
MHz, CDCl3): δ = 138.8, 129.3, 128.5,
127.8, 100.9, 81.8, 72.6, 72.2, 70.0, 54.0, 36.7, 27.7. ESI-MS: m/z = 277 [M]+.
Anal. Calcd (%) for C16H23NO3:
C, 69.31; H, 8.30. Found: C, 69.33; H, 8.27.
(4a
R
,6
S
,7a
S
)-Benzyl 6-Hydroxymethyl)-2,2-dimethyl-tetrahydro[1,3]dioxino[5,4-
b
]pyrrole-5(6
H
)-carboxylate (2)
[α]D
²5 -55.4
(c 1.0, CHCl3). ¹H
NMR (300 MHz, CDCl3):
δ = 7.32-7.13
(5 H, m), 5.05 (2 H, s), 4.40 (1 H, m), 4.24-4.00 (2 H,
m), 3.96-3.65 (4 H, m), 3.07 (1 H, m), 2.63 (1 H, br s),
2.25 (1 H, m), 1.47 (6 H, s). ¹³C NMR
(75 MHz, CDCl3): δ = 155.8, 135.5,
129.0, 128.7, 128.5, 127.8, 100.1, 72.0, 68.5, 67.0, 66.2, 61.1,
58.6, 31.4, 29.5, 19.8. ESI-MS: m/z = 321 [M]+.
Anal. Calcd (%) for C17H23NO5:
C, 63.55; H, 7.17. Found: C, 63.51; H, 7.12.